Big Pharma Is Pouring Billions Into China’s Biotechs
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Top global stories this week; markets rally on rate-cut optimism
US stock indexes ended the week higher driven by bargain hunting in technology stocks, cooling geopolitical tensions, and renewed optimism that a slowing U.S. labor market [https://seekingalpha.com/news/4609641-us-jobless-claims-fall-to-21…
AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC
[AstraZeneca company office building] Robert Way/iStock Editorial via Getty Images AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) has reached a partnership worth up to $1.77B with CSPC Pharmaceutical Group (CSPCY [https://seeking…
The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
The EGFR-NSCLC pipeline possesses some drugs in late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (CLN-081) (Cullinan On…
CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSPC Pharmaceutical Group (SEHK:1093) has received regulatory approval in China to start clinical…
2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
SUZHOU, China, April 22, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the significant results from the Phase III clinical study (KN026-004) of HER2 bispecific antibody Anbenitamab Injection (KN026), ind…
Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
SUZHOU, China, April 1, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed with JMT-Bio Technol…
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
SUZHOU, China, March 24, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in the Phase III clinical study (KN026-007) of HER2 bispecific antibody Anbenitamab (KN026) in comb…
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003
SUZHOU, China, Feb. 14, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-005) of the biparatopic HER2-targeting ant…
AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC
AstraZeneca AZN announced that it has entered into a new strategic collaboration with China-based CSPC Pharmaceutical to develop several next-generation therapies for obesity and type 2 diabetes (T2D). Under this new deal, AstraZeneca aims…
CSPC AstraZeneca Deal Recasts Role In Global Obesity And Diabetes Therapies
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. CSPC Pharmaceutical Group and AstraZeneca have entered a global collaboration and licensing deal to co develop long acting t…
AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China's CSPC
By Andrew Silver SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related conditions from CSPC Pharmaceutical Group and collaborate on other projects, paying $1.2 billion upfront and up to $1…
AstraZeneca Agrees Up to $18.5 Billion Obesity Drug Deal in China
This article first appeared on GuruFocus. AstraZeneca (NASDAQ:AZN) is stepping more assertively into the obesity drug race, agreeing to pay China's CSPC Pharmaceutical Group up to $18.5 billion for a broad portfolio of weight-loss candidat…
Trending tickers: Apple, Microsoft, Sandisk, Caterpillar and AstraZeneca
Apple (AAPL) Shares in Apple fell in pre-market trading on Friday despite the company reporting first quarter earnings that beat expectations, as investors questioned the durability of a sharp sales rebound. NasdaqGS - Delayed Quote•USD (A…
AstraZeneca secures tie-up with Chinese firm for weight loss drugs
AstraZeneca has unveiled a tie-up with China’s CSPC Pharmaceutical Group to ramp up development of experimental weight loss and diabetes drugs in a deal worth 18.5 billion US dollars (£13.4 billion) as it looks to tap further into the boom…
Is CSPC Pharmaceutical Group (SEHK:1093) Still Attractive After A 129% One-Year Share Price Surge
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are wondering whether CSPC Pharmaceutical Group is still fairly priced after its strong run, this article explai…
Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
SUZHOU, China, Jan. 27, 2026 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of anbe…
Notable healthcare headlines for the week: UnitedHealth, Molina Healthcare, and Novo Nordisk in focus
Wall Street's major averages struggled to hold onto gains on Friday, with both the S&P 500 and the Nasdaq Composite seesawing on the first trading day of 2026. The benchmark S&P 500 ended +0.2%, while the Nasdaq Composite finished flat, an…
Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China
This article first appeared on GuruFocus. Novo Nordisk (NOVO, Financials) and Eli Lilly (LLY, Financials) are reducing prices for their leading obesity treatments, Wegovy and Mounjaro, in China to strengthen market share in the world's mos…
Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration
This article first appeared on GuruFocus. Novo Nordisk A/S (NVO, Financials) cut the price of its top selling weight loss medicine Wegovy in China on Monday, expecting tougher competition from Chinese pharmaceutical businesses when its pat…
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
SUZHOU, China, Dec. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio…
Health Care Roundup: Market Talk
Find insight on Novo Nordisk, CSPC Pharmaceutical Group and more in the latest Market Talks covering Health Care. Continue Reading View Comments
How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story
The Board of Directors of CSPC Pharmaceutical Group announced it has received approval from China's National Medical Products Administration to begin clinical trials for SYH2061 Injection, an ultra-long-lasting siRNA drug that targets comp…
Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals, Inc. Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to…
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio…
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug c…
Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session
SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company a…
How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook
The Board of Directors of CSPC Pharmaceutical Group recently announced that its novel SYH2070 siRNA injection received regulatory approval to begin clinical trials in both the U.S. and China for the treatment of hypertriglyceridemia and mi…
Analysis-Innovent's weight-loss drug highlights China challenge for Novo, Lilly
By Andrew Silver SHANGHAI (Reuters) -Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining tract…
The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration
SUZHOU, China, Sept. 12, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Tec…
Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight
The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168 (AlaMab Therapeutics in collaboration with CSPC Pharmaceutical), Naxitamab 15-096…
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Madrigal Pharmaceuticals, Inc. License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GL…
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
Rakovina Therapeutics Inc VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therap…
3 Asian Penny Stocks With Market Caps Below US$8B
Amidst global market turbulence, Asian markets have shown resilience, with Japan's stock indices experiencing modest gains and China's markets buoyed by stimulus hopes. In such an environment, investors often look for opportunities in smal…
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharma…
February 2025 Penny Stocks Worth Watching
As global markets edge toward record highs, driven by U.S. stock indexes and a surge in the Nasdaq Composite, investors are navigating a landscape marked by rising inflation and cautious monetary policy. In this context, penny stocks—often…